New Study Of Pfizer Vaccine Yields SHOCKING Results
New studies show full vaccination with the two-dose Pfizer COVID-19 vaccine has been 90% effective in protecting against hospitalization for at least six months.
Data for the study was collected during the time that the highly contagious Delta variant was circulating around the United States.
Researchers analyzed Kaiser Permanente Southern California data on approximately 3.4 million people who had received both doses of the Pfizer vaccine, the average time since being fully vaccinated was three to four months.
The study was conducted from Dec. 4 to Aug. 8, 2021, during that time 5.4% of those people were infected with the coronavirus, 6.6% of which were hospitalized.
Overall, vaccine effectiveness against all SARS-CoV-2 infections fell from 88% one month after receiving two doses of the vaccine to 47% six months post vaccine; however the effectiveness of the vaccine still reduced the severity of the virus further reducing the number of hospitalizations by 90%, the study showed.
Vaccine effectiveness against the Delta variant infections fell from 93% at one month after receiving the full dose to 53% four months post-vaccine, however still reduced the severity and need for hospitalization by 93%.
The findings, published Oct. 4 in The Lancet medical journal, are in line with initial reports from the U.S. Centers for Disease Control and Prevention and the Israel Ministry of Health showing declines in the Pfizer vaccine’s effectiveness against infection after about six months.
“Our study confirms that vaccines are a critical tool for controlling the pandemic and remain highly effective in preventing severe disease and hospitalization, including from the Delta and other variants of concern. Protection against infection does decline in the months following a second dose,” study lead author Dr. Sara Tartof, from the department of research & evaluation at Kaiser Permanente Southern California, said in a journal news release.
“While this study provides evidence that immunity wanes for all age groups that received the vaccine, the CDC Advisory Committee on Immunization Practices has called for additional research to determine if booster shots should be made available to all age groups eligible for this vaccine,” she noted.
“In line with the recent [U.S. Food and Drug Administration] and CDC recommendations, considerations for booster shots should take global COVID-19 vaccine supply into account as people in many countries around the world have not yet received a primary vaccination series,” Tartof added.